1. Home
  2. DVS vs DMAC Comparison

DVS vs DMAC Comparison

Compare DVS & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DVS

Dolly Varden Silver Corporation

HOLD

Current Price

$3.86

Market Cap

446.5M

Sector

N/A

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$7.28

Market Cap

428.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DVS
DMAC
Founded
2011
2000
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
446.5M
428.6M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
DVS
DMAC
Price
$3.86
$7.28
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.50
AVG Volume (30 Days)
1.1M
168.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.48
$3.22
52 Week High
$5.93
$10.42

Technical Indicators

Market Signals
Indicator
DVS
DMAC
Relative Strength Index (RSI) 33.79 34.97
Support Level $3.30 $6.56
Resistance Level $3.96 $7.30
Average True Range (ATR) 0.26 0.42
MACD -0.07 -0.08
Stochastic Oscillator 0.00 14.16

Price Performance

Historical Comparison
DVS
DMAC

About DVS Dolly Varden Silver Corporation

Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: